US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Praxis Precision Medicines, Inc. - Common Stock
(NQ:
PRAX
)
295.51
+8.60 (+3.00%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Praxis Precision Medicines, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis (PRAX) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Two FDA applications advance as cash runway extends into 2028.
Via
The Motley Fool
Topics
Earnings
Praxis Precision Medicines (NASDAQ:PRAX) Beats Q1 Estimates as FDA Accepts Two Key Drug Applications
↗
May 07, 2026
Via
Chartmill
Praxis Precision Medicines Q2 Earnings Call Highlights
↗
August 07, 2026
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and...
Via
MarketBeat
Topics
Earnings
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 06, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
July 30, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
July 07, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
June 29, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
June 22, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
June 04, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Vormatrigine Program Update
June 01, 2026
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
↗
May 31, 2026
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
Via
The Motley Fool
Topics
Regulatory Compliance
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
↗
May 31, 2026
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
↗
May 26, 2026
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Stocks
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
↗
May 21, 2026
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
Via
The Motley Fool
Topics
Intellectual Property
Regulatory Compliance
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
↗
May 21, 2026
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.
Via
The Motley Fool
Topics
Economy
Regulatory Compliance
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
↗
May 17, 2026
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Via
The Motley Fool
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
↗
May 17, 2026
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
↗
May 17, 2026
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
Via
The Motley Fool
Topics
Regulatory Compliance
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
↗
May 17, 2026
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
↗
May 17, 2026
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Via
The Motley Fool
Topics
Regulatory Compliance
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
↗
May 17, 2026
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Via
The Motley Fool
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
↗
May 17, 2026
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Via
The Motley Fool
Topics
Regulatory Compliance
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
↗
May 16, 2026
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
Via
The Motley Fool
Topics
Regulatory Compliance
Praxis (PRAX) Q1 2026 Earnings Call Transcript
↗
May 12, 2026
Praxis (PRAX) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Praxis Precision Medicines Q1 Earnings Call Highlights
↗
May 08, 2026
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026...
Via
MarketBeat
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
